ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > U.S. COVID/ sars Cov2 serology over a billion

<< Previous

Bullboard Posts

Next >>

Post by Gbathaton Apr 25, 2021 10:41pm

254 Views

Post# 33064790

U.S. COVID/ sars Cov2 serology over a billion

https://www.medtechdive.com/news/as-antibody-tests-proliferate-analysts-see-multibillion-dollar-market-for/576408/

U.S. COVID/ sars Cov2 serology over a billion

So let's guess $5B worldwide and 10% market capture for $500M in revs for JV, so $250M revs. Let's say 25% margin, or about $63M in earnings. And a P/E of 25 due to future growth potential.

That would be a market cap of $1.5B USD.

Current market cap is $46M. So 32-fold increase in pps if that played out.

Just wild estimates at this point, but one can dream.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages